Andrew Lin, MD
Neuro-Oncologist & Neurologist
Memorial Sloak Kettering Cancer Center
After registering you will receive a confirmation email with details about joining the webinar.
Contact us at email@example.com with any questions or suggestions.
Date: September 18, 2019
Time: 10:00 AM – 11:00 AM. Pacific Daylight Time, 1:00 PM – 2:00 PM Eastern Daylight Time
During the conversation I will be:
1) Defining aggressive pituitary tumors.
2) Reviewing the current treatment options for aggressive pituitary tumors.
3) Discussing experimental treatment options including a phase II trial investigating the activity of the immunotherapies nivolumab and ipilimumab.
I am a neuro-oncologist at Memorial Sloan Kettering Cancer Center (MSK) and a member of the Multidisciplinary Pituitary & Skull Base Tumor Center. In collaboration with my colleagues in endocrine, neurosurgery, and radiation oncology, I treat patients with aggressive pituitary tumors, who are resistant to conventional treatments (i.e. surgery and radiation), with chemotherapy. With my colleagues at MSK, I have published several research articles on pituitary tumors and opened several clinical trials.